Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.

Autor:	Spelman T; Department of Medicine and Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia., Meyniel C; Department of Medicine and Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia.; Department of Neurophysiologie, Pitié-Salpêtrière Hospital, Paris, France., Rojas JI; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Lugaresi A; MS Center, Department of Neuroscience and Imaging, University 'G. d'Annunzio', Chieti, Italy., Izquierdo G; Hospital Universitario Virgen Macarena, Sevilla, Spain., Grand'Maison F; Neuro Rive-Sud, Hôpital Charles LeMoyne, Greenfield Park, QC, Canada., Boz C; Karadeniz Technical University, Trabzon, Turkey., Alroughani R; Amiri Hospital, Kuwait City, Kuwait., Havrdova E; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, General University Hospital and Charles University in Prague, Prague, Czech Republic., Horakova D; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, General University Hospital and Charles University in Prague, Prague, Czech Republic., Iuliano G; Ospedali Riuniti di Salerno, Salerno, Italy., Duquette P; Hôpital Notre-Dame, Montreal, QC, Canada., Terzi M; Ondokuz Mayis University, Samsun, Turkey., Grammond P; Centre de réadaptation en déficience physique Chaudière-Appalaches, Levis, QC, Canada., Hupperts R; Maaslandziekenhuis, Sittard, The Netherlands., Lechner-Scott J; John Hunter Hospital, Newcastle, NSW, Australia., Oreja-Guevara C; Hospital Clínico San Carlos, Madrid, Spain., Pucci E; Neurology Unit, ASUR Marche - AV3, Macerata, Italy., Verheul F; Groene Hart Ziekenhuis, Gouda, The Netherlands., Fiol M; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia, Buenos Aires, Argentina., Van Pesch V; Cliniques Universitaires Saint-Luc, Brussels, Belgium., Cristiano E; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Petersen T; Kommunehospitalet, Aarhus, Denmark., Moore F; Jewish General Hospital, Montreal, QC, Canada., Kalincik T; Department of Medicine and Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia., Jokubaitis V; Department of Medicine and Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia., Trojano M; Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy., Butzkueven H; Department of Neurology, Box Hill hospital, Monash University, Box Hill, VIC, Australia.
Jazyk:	angličtina
Zdroj:	Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2017 Sep; Vol. 23 (10), pp. 1346-1357. Date of Electronic Publication: 2016 Nov 25.
DOI:	10.1177/1352458516679893
Abstrakt:	Background: Characteristics at clinically isolated syndrome (CIS) examination assist in identification of patient at highest risk of early second attack and could benefit the most from early disease-modifying drugs (DMDs). Objective: To examine determinants of second attack and validate a prognostic nomogram for individualised risk assessment of clinical conversion. Methods: Patients with CIS were prospectively followed up in the MSBase Incident Study. Predictors of clinical conversion were analysed using Cox proportional hazards regression. Prognostic nomograms were derived to calculate conversion probability and validated using concordance indices. Results: A total of 3296 patients from 50 clinics in 22 countries were followed up for a median (inter-quartile range (IQR)) of 1.92 years (0.90, 3.71). In all, 1953 (59.3%) patients recorded a second attack. Higher Expanded Disability Status Scale (EDSS) at baseline, first symptom location, oligoclonal bands and various brain and spinal magnetic resonance imaging (MRI) metrics were all predictors of conversion. Conversely, older age and DMD exposure post-CIS were associated with reduced rates. Prognostic nomograms demonstrated high concordance between estimated and observed conversion probabilities. Conclusion: This multinational study shows that age at CIS onset, DMD exposure, EDSS, multiple brain and spinal MRI criteria and oligoclonal bands are associated with shorter time to relapse. Nomogram assessment may be useful in clinical practice for estimating future clinical conversion.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu